Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

Search

Medicines Law & Policy Research and resources on intellectual property and health

Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

Tag: GAVI

The € 7.4 billion for Covid-19 product and vaccine development needs...

Ellen 't Hoen - May 5, 2020

Recent Posts

Protecting Public Health through Technology Transfer: The Unfulfilled Promise of the TRIPS Agreement
How not to solve a crisis: The European Commission’s Plan for Transferable Data Exclusivity Vouchers
Right to breathe takes precedence over company profits: Families of cystic fibrosis patients seek access to life-saving drug in face of company intransigence
ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the Pandemic Accord

Posts by Subject

Abbvie Access to Medicines Access to Vaccines ARIPO AstraZeneca C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Covid-19 vaccine Data exclusivity Delinkage DNDi European Commission European Union evergreening Fair Pricing Gilead Hepatitis C human rights IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands Orphan Drugs pandemic treaty Patents R&D remdesivir Sofosbuvir technology transfer The Netherlands transparency TRIPS Council TRIPS flexibilities TRIPS Waiver vaccines WHO WTO

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

This work is licensed under Creative Commons.